EyePoint Pharmaceuticals (EYPT) Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ CALM Registry Study at ASRS 39th Annual Meeting
- Tech lifts S&P 500, Nasdaq amid inflation, China growth worries
- Zillow (ZG) Stock Falls on Report Company Paused Home Purchases due to High Demand, a Temporary Halt Yields a Chance for Competitors Says Analyst
- Oil prices ease off highs as U.S. factory data weighs on market
- Chip Shortages are Increasingly Becoming a New Bearish Risk, Inflation Bearish for Consumer Electronics - TFI's Kuo
- Walt Disney (DIS) Stock Slips as Barclays Downgrades Amid Disney+ Growth Slowdown
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced positive interim safety data from its Phase 1 clinical trial of EYP-1901, a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD), and preliminary results from YUTIQ® CALM, a real-world registry study of the fluocinolone acetonide intravitreal (FAi) implant 0.18 mg in chronic noninfectious posterior uveitis. The two studies were presented in a Paper-On-Demand and an ePoster Presentation, respectively, at the American Society of Retina Specialists (ASRS) 39th Annual Meeting held October 8 – 12, 2021.
“We are excited to report that preliminary 3-month safety data for all patients from our ongoing DAVIO trial of EYP-1901 continues to demonstrate an excellent safety profile with no serious ocular or systemic adverse events reported to date,” said Nancy Lurker, CEO of EyePoint Pharmaceuticals. “These results support EYP-1901’s potential to provide wet AMD patients with a safe, effective and long-term therapeutic option. We are also pleased to present preliminary results from the CALM registry study, which allows us to better understand the patients we serve, and, subsequently, how we can ensure that YUTIQ, using EyePoint’s proprietary Durasert® technology, remains the most effective and innovative solution for our patients’ unmet needs.”
Summaries of the ASRS presentations are as follows:
Title: Initial Safety Results of the DAVIO Trial: An Open Label, Dose Escalation Phase 1 Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI) in Subjects with Wet AMDPresenters: Vrinda S. Hershberger, MD, PhD; David R. Lally, MD; Mark R. Barakat, MD and Dario A. Paggiarino, MDType: On-Demand Poster Presentation
The Phase 1 DAVIO open-label, dose escalation trial clinical trial of EYP-1901 enrolled 17 wet AMD patients across three dose cohorts. The study is ongoing, and all patients were previously treated with standard of care anti-VEGF therapies. Key safety observations through at least 3-months post-dosing for all patients include that no serious adverse events (SAEs), ocular or systemic, were reported. 21 ocular adverse events (AEs) were reported, all mild (19) to moderate (2) in severity, and there have been no reported AEs related to significant intraocular inflammation, best corrected visual acuity (BCVA) reduction, or elevation of intra-ocular pressure (IOP). No events of endophthalmitis, retinal detachment, or migration into the anterior chamber have been reported to date.
EyePoint plans to release interim efficacy results once the study has sufficient follow-up data for all dose cohorts later in the fourth quarter of this year.
Title: YUTIQ® CALM: A Real-World Registry Study of the Fluocinolone Acetonide Intravitreal Implant 0.18 Mg in Chronic Noninfectious Posterior UveitisPresenters: Ankur Shah, M.D. and Rene Choi, M.D.Type: ePoster Presentation
The ongoing YUTIQ CALM real-world registry study is collecting data on patients who have received the fluocinolone acetonide intravitreal implant 0.18 mg. This study included patients of 18 years of age and older with a diagnosis of chronic noninfectious uveitis affecting the posterior segment and no contradictions to the FAi. Baseline and follow-up data are collected retrospectively and include central subfield thickness (measured via optical coherence tomography); best-corrected visual acuity; presence of inflammation; use of concomitant anti-inflammatory medications; and incidence of adverse events. Interim baseline data on patients in the registry as of August 2021 reveal that patients feature a substantial duration of uveitis (mean 57 months, or about 4.75 years), a variety of etiologies (largely unknown) and previous treatments (most often topical, intraocular and systemic corticosteroids and immunomodulatory drugs) in their medical history. Ocular characteristics include the presence of macular edema (mean CST 353.56 microns), relatively poor BCVA (mean 55.15 ETDRS letters) and an IOP generally in normal range (mean 13.35 mmHg). Most patients had relatively controlled intraocular inflammation as measured by AC cell and vitreous haze.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Moleculin (MBRX) Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for Treatment of Soft Tissue Sarcoma Lung Metastases
- LogicBio Therapeutics (LOGC) Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children
- DiaMedica Therapeutics Inc. (DMAC) to Report Late Breaking Data from REDUX Phase 2 Trial
Create E-mail Alert Related CategoriesCorporate News, FDA
Related EntitiesTwitter, Dividend, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!